Investigation announced for Investors in shares of Cortexyme, Inc. (NASDAQ: CRTX)

An investigation on behalf of investors of Cortexyme, Inc. (NASDAQ: CRTX) shares over potential securities laws violations by Cortexyme, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

Investors who purchased shares of Cortexyme, Inc. (NASDAQ: CRTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Cortexyme, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders.

On October 26, 2021, Cortexyme, Inc. issued a press release "report[ing] top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis)." The press release reported, in relevant part, that the study had failed to meet statistical significance in its co-primary endpoints of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer's disease.

Then, on January 26, 2022, Cortexyme disclosed receipt of a letter from the U.S. Food and Drug Administration ("FDA") advising that the FDA had "plac[ed] a full clinical hold on atuzaginstat's (COR388) Investigational New Drug application (IND 134303)."

Shares of Cortexyme, Inc. (NASDAQ: CRTX) declined from $98.50 per share on Octboer 5, 2021, to as low as $5.31 per share on January 28, 2022.

Those who purchased shares of Cortexyme, Inc. (NASDAQ: CRTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.